Clinical Trials Browser

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

NCT03810105 2024-04-09

A Study of Olaparib and Durvalumab in Prostate Cancer

Phase 2 Terminated

5 enrolled 4 charts

Genitourinary

Prostatic Neoplasms

NCT04610684 2024-03-13

Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases

Phase 2 Terminated

3 enrolled 13 charts

CNSThoracic

Brain Neoplasms, Small Cell Lung Carcinoma

NCT03840902 2024-01-16

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Phase 2 Terminated

153 enrolled 13 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03490760 2023-10-12

Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas

Phase 2 Terminated

9 enrolled 12 charts

Gastrointestinal

Adenocarcinoma of the Pancreas

NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Phase 2 Terminated

7 enrolled 9 charts

GenitourinarySarcoma

Bladder Adenocarcinoma

NCT04372927 2023-06-13

ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy

Phase 2 Terminated

1 enrolled 10 charts

Thoracic

Lung Neoplasms

NCT03030131 2023-03-14

IONESCO

Phase 2 Terminated

50 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02807454 2023-02-21

FUSIONMM-003

Phase 2 Terminated

37 enrolled 21 charts

Plasma cell

Multiple Myeloma, Recurrence

NCT02901548 2022-07-29

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Phase 2 Terminated

17 enrolled 9 charts

Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT03874325 2022-05-31

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Phase 2 Terminated

17 enrolled 10 charts

Breast

Breast Neoplasms

NCT04579133 2021-06-16

Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy

Phase 2 Terminated

140 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03081923 2021-05-14

APACHE

Phase 2 Terminated

36 enrolled

Genitourinary

Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms

NCT03234153 2020-06-17

NITIMIB

Phase 2 Terminated

6 enrolled

Genitourinary

Muscle-invasive Bladder Cancer

NCT02452463 2020-04-06

Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy

Phase 2 Terminated

8 enrolled 25 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Radiation Pneumonitis

NCT02669914 2018-11-06

MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors

Phase 2 Terminated

4 enrolled 12 charts

BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Clinical Trials

Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

BOLSTER

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC

DUTHY

AMTEC IIT: Phase 2 Multiarm Study in TNBC

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

BRIDGE

Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

ESR1814205

Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

--SuPERIOR Trial--

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

A Study of Olaparib and Durvalumab in Prostate Cancer

Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy

IONESCO

FUSIONMM-003

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy

APACHE

NITIMIB

Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy

MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors